CCND1 and neoplasm: Besides, several studies have confirmed that targeted therapy for BRAFV600E‐mutant tumours may restore cyclin D1 expression, promoting the cell cycle from the initial growth phase to the synthesis phase, which enables a group of cancer cells to resist cytotoxic effects, thereby generating a resistant tumour cell subpopulation30, 32 (Figure 2).